We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -1.40 | -0.14% | 983.40 | 2,111,695 | 16:35:22 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 983.60 | 984.00 | 991.40 | 982.40 | 989.80 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Ortho,prosth,surg Appl,suply | USD 5.55B | USD 263M | USD 0.3011 | 32.67 | 8.59B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 18:45:01 | O | 69,808 | 984.792 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 23/4/2024 | 09:46 | UK RNS | Smith & Nephew Plc Timing of Smith+Nephew Q1 2024 Trading Report |
| 18/4/2024 | 12:00 | UKREG | Smith+Nephew announces new evidence supporting ALLEVYN LIFE Foam Dressing’s.. |
| 04/4/2024 | 16:13 | UKREG | Smith+Nephew’s PICO™ Single Use Negative Pressure Wound Therapy System.. |
| 02/4/2024 | 13:43 | UK RNS | Smith & Nephew Plc Total Voting Rights |
| 02/4/2024 | 13:19 | UK RNS | Smith & Nephew Plc Director/PDMR Shareholding |
| 28/3/2024 | 09:37 | ALNC |  Smith & Nephew CFO designate John Rogers to start next week |
| 28/3/2024 | 07:00 | UK RNS | Smith & Nephew Plc Directorate Change |
| 25/3/2024 | 12:00 | UKREG | Smith+Nephew teams up with UFC to be first-ever Preferred Sports Medicine.. |
| 14/3/2024 | 11:53 | ALNC | IN BRIEF: Smith & Nephew prices USD1 billion in debt notes |
| 14/3/2024 | 07:00 | UK RNS | Smith & Nephew Plc SMITH+NEPHEW PRICES USD BOND ISSUE |
Smith & Nephew (SN.) Share Charts1 Year Smith & Nephew Chart |
|
1 Month Smith & Nephew Chart |
Intraday Smith & Nephew Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 17/4/2024 | 18:39 | *** Smith and Nephew *** | 724 |
| 29/10/2015 | 08:48 | SN. | 122 |
| 10/1/2011 | 13:03 | Smith and Nephew 2008 | 67 |
| 09/1/2011 | 17:12 | Smiths: Charts and News etc. | 296 |
| 25/9/2006 | 15:09 | Smith&Nep. Why the rise? | 75 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-04-24 17:45:02 | 984.79 | 69,808 | 687,463.60 | O |
| 2024-04-24 17:16:52 | 985.00 | 3,460 | 34,080.93 | O |
| 2024-04-24 17:09:56 | 985.93 | 2,717 | 26,787.83 | O |
| 2024-04-24 17:09:41 | 982.91 | 12,260 | 120,504.77 | O |
| 2024-04-24 17:09:41 | 984.27 | 1,636 | 16,102.62 | O |
| Top Posts |
|---|
Posted at 24/4/2024 09:20 by Smith & Nephew Daily Update Smith & Nephew Plc is listed in the Ortho,prosth,surg Appl,suply sector of the London Stock Exchange with ticker SN.. The last closing price for Smith & Nephew was 984.80p.Smith & Nephew currently has 873,398,889 shares in issue. The market capitalisation of Smith & Nephew is £8,592,498,270. Smith & Nephew has a price to earnings ratio (PE ratio) of 32.67. This morning SN. shares opened at 989.80p |
Posted at 11/4/2024 22:56 by its the oxman Stryker has grown its share price over 400% in that time. Perhaps we are in the wrong stock. At least we yield more but that's also the story of the uk market. |
Posted at 11/4/2024 22:40 by its the oxman c.10 years ago the price was much the same as it is today. Hard to believe. |
Posted at 06/3/2024 13:38 by cerrito Interested to read this in Citywirequote he market has an ‘unconscious bias’ against Smith & Nephew (SN) and always assumes the worst about the medical technology company, says Liberum. Analyst Seb Jantet retained his ‘buy’ recommendation and target price of £12.85 on the Citywire Elite Companies AA-rated provider of hip and knee implants, which rose 0.3% to £10.46 on Tuesday. ‘We are slightly perplexed by the market’s reaction to Smith & Nephew’s full-year results,’ Jantet said. ‘Trading was in line and there was a solid guide for full year 2024. And while the initial share price reaction was positive, the shares fell sharply over the next few days. ‘Understandabl He added that ‘both the revenue and margin guides are achievable’ and said the ‘discount to peers is too high’. |
Posted at 28/2/2024 23:21 by lonrho Smith and nephew price about 13 dollars ,stryker 350 dollars so maybe no . |
Posted at 17/12/2023 22:56 by shabirm Do UBS and Goldman know what they are talking about with target price differential of neay 30% from current share price. That says a lot about professional analysis. |
Posted at 15/12/2023 15:56 by philanderer or........UBS cuts Smith & Nephew price target to 1,090 (1,150) pence - 'neutral' |
Posted at 12/10/2023 15:36 by lonrho 2010 seems to be the peak year with a trading profit of 969k and a margin of 24.4% compared to 2022 with 901k trading profit and a margin of 17.2%. Rupert Soames did a good job of sorting out Serco so hopefully he can make a difference now he is chairman here. By mid 2014 share price was £11 despite profits reducing from 2010 onwards. |
Posted at 12/10/2023 14:58 by essentialinvestor Laurence, part of the issue is arguably their main competitors growing strongerv SN over the last decade. This may account for some of SN's weaker metrics. While a bid can't be ruled out, it has been mentioned as a takeover candidate for decades. If you go back 10 years, this was a high margin business with low gearing and a prodigious cash generator. Those bullish on SN may say that's now reflected in the current share price, however circa 2013, at approx £8 plus a share you were buying at the time a great business. |
Posted at 27/9/2023 20:00 by pugugly Too many of those needing our product - in particular hips in the UK - having operations delayed - once twice or more times by the medics who have abandoned the Hippocratic Oath and are holding the NHS to ransom and condemning too many of the mainly elderly to ongoing pain which could be relieved by surgery.Results - Significant number of possible beneficiaries pass over in pain before they can receive an operation so no longer potential beneficiaries - fall in usage reduces S&N revenue and cash flow = fall in share price - takeover potential and yet another British company crosses the ocean reducing GB plc's revenue and tax base. Not yet low enough (imo) to attract a bid - Could easily need to drop another 10%+ or so.; |
Posted at 18/8/2023 09:01 by pugugly Looks as though going to hell on a broomstick -All brokers targets well under water - Any value - ie:- share price growth potential - peg and p/e seem very high given share price history. Share price at time of posting 1072p .Smith & Nephew Broker views Date Broker Recomm. Old target price New target price Notes 20/07/2023 JP Morgan Cazenove Neutral - - Reiteration 03/07/2023 JP Morgan Cazenove Neutral - 1,612.00p Reiteration 15/06/2023 Citigroup Buy - - Reiteration 16/05/2023 Berenberg Bank Buy 1,400.00p 1,500.00p Reiteration 02/05/2023 Berenberg Bank Buy 50.00p 60.00p Reiteration 27/04/2023 Barclays Underweight 1,100.00p 1,200.00p Reiteration 14/03/2023 Citigroup Buy - - Reiteration 08/03/2023 Berenberg Bank Buy - 1,400.00p Reiteration 01/03/2023 Liberum Capital Buy 1,120.00p 1,410.00p Upgrade 17/11/2022 Berenberg Bank Buy 1,400.00p 1,400.00p Reiteration |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
